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INTRODUCTION: Renal cancer is a relatively common neoplasia with renal clear cell carcinoma being the
most frequent histological type. This tumor has a strong tendency to metastasize virtually to all organs.
Today, new diagnostic tools allow physicians to distinguish between those patients with “incidental
ﬁndings” and those with advanced metastatic disease.
PRESENTATION OF CASE: A 70-year-old male with multiple indolent subcutaneous masses underwent
colonoscopy after a positive fecal screening test for colorectal carcinoma. A rectal lesion was discov-
ered but biopsy was negative. CT scan revealed advanced renal cancer involving the peritoneal cavity,
retroperitoneum and lung. Biopsy of subcutaneous masses conﬁrmed the suspected metastases. The
patient underwent surgery (an open left nephrectomy with rectosigmoid resection and metastases
debulking) because of a high risk of bowel obstruction and increasing anemia. After three years of
multi-targeted therapy and follow-up, the patient is still asymptomatic and in good general condition.
DISCUSSION: Treatment of metastatic renal cancer is still controversial even if more than 30% of patients
have metastasis at the time of diagnosis. Recently introduced targeted therapies are encouraging but still
present problems with side effects and an unlimited period of efﬁcacy. Although there is no consensus,
several studies and guidelines consider metastasectomy to be a valid option.
CONCLUSION: Recent series highlight surgery as a key-point in the management of advanced renal clear
cell carcinoma. Our case demonstrates the validity of a surgical strategy supported by a multidisciplinary
approach.
© 2015 The Authors. Published by Elsevier Ltd. on behalf of Surgical Associates Ltd. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Renal cancer is a relatively common neoplasia, with approxi-
mately 11,800 cases per year in Italy, amounting to 3% of all adult
malignancies [1]. Renal clear cell carcinoma (RCC) is the most fre-
quent histological type, representing 60% of cases with the highest
incidence occurring in individuals between 50 and 70 years of age.
Renal cancer is theurological tumorwith thehighestmortality rate.
Its aggressive behavior, due to a strong tendency to metastasize
(30% of cases are metastatic at time of diagnosis or during follow-
up) is associated with 14,000 estimated deaths in 2015 in the USA
[2].
While in the past, RCC typically presented as hematuria, ﬂank
pain or palpablemass in the abdomen,most cases today are asymp-
tomatic at timeof discovery, due to the availability ofmore accurate
diagnostic tools. This trend has resulted in a greater separation
between cases presenting as “incidental ﬁndings” and those with
advanced metastatic disease.
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RCC’s strong tendency to metastasize is mainly due to complex
and rich vascularization and its lymphatic drainage. Themajor sites
of metastasis are lung [75%], bone [20%], lymph nodes [11%], liver
[18%], and brain [8%] but virtually all organs can be affected [3].
2. Presentation of case
The patient, a 70-year-old man with a history of hyperten-
sion, diabetes and multiple indolent subcutaneous masses, after
a positive screening fecal test for colorectal carcinoma, underwent
colonoscopy. The patient was asymptomatic, with neither rectal
bleeding nor hematuria.
The endoscopist described a smooth ﬂat lesion occupying one-
third of the colonic lumen extending for 5 cm, characterized by
rich superﬁcial vascularization with no mucosal ulceration, 20 cm
from the anal verge. Biopsy samples showed non-speciﬁc lympho-
cytic inﬂammation with edema of the colonic mucosal wall. The
main tumor markers were normal: CEA 1ng/mL, Ca19-9 3.1U/mL,
PSA 0.39ng/mL, CA-72.4 1.1U/mL. Renal function was conserved.
The patient underwent whole body CT scan which revealed mul-
tiple nodular masses occupying the entire peritoneal cavity, pelvis
and retroperitoneum, ranging from a few millimeters up to 4 cm
in the retroperitonum and 8cm in the pelvis (Fig. 1). Speciﬁcally,
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Fig. 1. Abdominal CT scan.
theposterior aspect of the left kidneywasoccupiedby anexpansive
process penetrating the para- and perirenal spacewith amaximum
transverse diameter of 11 cm. The lungswere involvedwith lesions
of secondary aspectwith intense contrast enhancement and subcu-
taneous tissuewas characterized bymultiple lumps ranging from1
to 10 cm. Surprisingly, the liver, pancreas, spleen and bladder were
free of pathologic ﬁndings.
Following the CT scan, the patient was sent to our department
for surgical evaluation. Physical inspection conﬁrmed the presence
of palpable masses in the left abdomen and multiple subcuta-
neous lesions of parenchymatous consistency in the patient’s arms,
back and chest that he reported as having had for years and that
were always considered as benign lipomas. We decided to biopsy
one subcutaneous lesion, located in the left chest wall, and his-
tology identiﬁed it as clear cell carcinoma of possible renal origin
(AE1/AE3+, CDK7−/+, Vimentin+, CD10+, TTF1−).
Although there is no sure evidence of major clinical beneﬁt of
surgery in metastatic renal cancer [4] after consulting with the
pathologist and the oncologist, we decided to proceed to surgery
mainly because of a high risk of bowel obstruction and increasing
anemia due to recurrent rectal bleeding. Another purpose was to
permit subsequent chemotherapy after massive cytoreduction of
the neoplasia with possibly better efﬁcacy [5,6].
The operation performed was an open left nephrectomy with
rectosigmoid resection, because of two hypervascularized soft
masses of 5 and 7 cm involved in the rectosigmoid junction. We
also proceeded with debulking of three omental macrometastases
of about 5 cm each (Fig. 2). Peritoneal multiple metastasectomy
Fig. 2. Omental metastases.
completed the procedure (Fig. 3). No macroscopic radicality (R0)
was achieved.
Surgical specimen examination revealed that the posterior of
the kidneywas completely substituted by a smooth hypervascular-
ized 10 cm mass involving perirenal fat and retroperitoneal space
(Fig. 4). Deﬁnitive histology conﬁrmed a 10 cm renal clear cell car-
cinoma inﬁltrating perirenal fat, the left adrenal gland, omentum,
sigmoid colon (Fig. 5), subdiaphragmatic stromas and subcuta-
neous tissues. The renal pedicle was free of metastatic inﬁltration
as were surgical margins of the excised recto-sigmoid tract; pT4,
pNx, pM1 (AJCC, TNM-2010).
The patient was referred to the oncologists for adjuvant
chemotherapy. After 6 months of selective multi-target receptor
tyrosine kinase inhibitor therapy (Pazopanib), the whole body CT
scan demonstrated a diffuse reduction of thoraco-abdominal resid-
ual disease. After another 6 months of the same therapy, a new
CT scan revealed no dimensional variation in the lesions. Almost
3 years after surgery, the patient is still asymptomatic, receiving
home chemotherapy (Sunitinib) and is in good general condition.
His most recent CT scan conﬁrmed the stability of his neoplasia.
3. Discussion
Metastatic renal cancer is a relatively common event with more
than 30% of patients presenting with a metastasis at the time of
diagnosis, even with non-palpable and asymptomatic renal mass.
As explained by Krumerman and Garret [7], the pattern of spread
is almost always unpredictable, mainly due to deep angioinvasion
Fig. 3. Mesenteric metastases.
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Fig. 4. Left kidney.
and complex lymphatic drainage. However, there is a predilection
for certain metastatic sites such as the lung [75%], bone [20%], liver
[18%], cutaneous sites [8%] and central nervous system [8%] [3]. As
a result, atypical metastases are considered those localized in a site
other than thoracic, skeletal, hepatic, adrenal or encephalic [8]. The
peritoneum, gut, mesentery and omentum are atypical sites and
extremely rare, affecting only 1% of patients with metastatic renal
cancer upon autopsy examination. Peritoneal and retroperitoneal
diffusion is associated with poor prognosis [9–11]. Our review of
the literature was unable to ﬁnd any cases of indolent diffuse renal
cancer simultaneously involving the peritoneum, retroperitoneum,
omentum, lung, subcutaneous tissue, colon and adrenal gland but
with no liver and bone involvement. Our case is probably one of the
ﬁrst reported. In such cases, it is always challenging todecidewhich
therapy is the best choice, especially when a surgeon is requested
to perform a non-codiﬁed surgical procedure. The treatment of
metastatic renal cancer is still controversial since large series of
metastasectomies are reported in the literature, but little is known
about the management of metastasis in atypical sites [8,12].
Although there is still no clear consensus about theuse ofmetas-
tasectomy, this would be a valid option, as supported by several
studies and recent guidelines [8,4,13] and by the fact that until
today, the treatment of metastatic renal carcinoma with systemic
therapyhas been rather unsuccessful. Recently introduced targeted
therapies are problematic because of side effects and their need to
Fig. 5. Sigmoid colon metastases.
be taken for an unlimited period of time [14,15]. Ongoing phase 3
studies on targeted therapies are recruiting patients but the results
are premature and require conﬁrmation [16–18].
Cytoreductive metastasectomy associated with nephrectomy is
an option but the main limitations are the need of good overall
health and functional status of the patient. Patients with a single
kidney, poor renal function or caval involvement are not candi-
dates for surgery. In our opinion, there is a rationale for surgery in
association with targeted therapies in the treatment of metastatic
RCC, although the timing and treatment sequence are still to be
established.
Available studies demonstrate the potential of long-term sur-
vival after complete surgical resection of multiple metastases in
patients with metastatic RCC as well as clinical beneﬁt even with
incomplete surgical resection. Five-year survival rates were 45%,
23% and 8% in one series and 49.4%, 23.7% and 8.9% in another series
for patients who underwent complete surgical resection, incom-
plete surgical resection, and no resection, respectively [13,19].
Surgical resection remains a critical mode of achieving control of
long-termdisease inmetastaticRCCpatients.However, prospective
studies are recommended to deﬁne surgical indications.
4. Conclusion
Our case demonstrates the validity of this approach with the
clinical evidence of our surgical and medical strategy. We hope
that a multidisciplinary approach, with the advent of new targeted
therapies, associated with complete surgical resection of the pri-
mary tumor and metastases will lead to advanced metastatic RCC
becoming a more indolent and chronic disease [20].
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